CANCER THERAPY BY COMBINED USE OF ONCOLYTIC SMALLPOX VACCINE VIRUS AND IMMUNE CONTROL POINT INHIBITOR, AND PHARMACEUTICAL COMPOSITION AND COMBINED DRUG FOR USE IN CANCER THERAPY Russian patent published in 2023 - IPC A61K35/768 A61K39/395 A61K48/00 A61P35/00 

FIELD: pharmaceutics; medicine.

SUBSTANCE: object 1 is a combined drug for use in the treatment of cancer, containing a pharmaceutical composition containing a smallpox vaccine virus as an active ingredient, where the smallpox vaccine virus is (1) a smallpox vaccine virus including polynucleotide encoding interleukin-7 (hereinafter – IL-7) and a smallpox vaccine virus including polynucleotide encoding interleukin-12 (hereinafter – IL-12), or (2) a smallpox vaccine virus including polynucleotide encoding IL-7 and polynucleotide encoding IL-12, and a pharmaceutical composition containing an immune control point inhibitor. Object 2 is a method for the treatment of cancer, including administration of the immune control point inhibitor and the smallpox vaccine virus.

EFFECT: antitumor effect and full remission induction effect revealing relatively to remote tumor, into which a smallpox vaccine virus was not administered, in case of the use of the smallpox vaccine virus in a combination with an immune control point inhibitor.

16 cl, 1 dwg, 1 ex